Novo Nordisk and Eli Lilly dominate the $150bn weight-loss drug market

In the burgeoning weight-loss drug market, Novo Nordisk's Wegovy and Eli Lilly's Zepbound lead the charge, with estimates pegging the sector at $150 billion by the early 2030s. Novo Nordisk's amycretin promises a substantial 13.1% weight loss, while Eli Lilly's Zepbound gained rapid approval and significant early sales. Other contenders like Pfizer, Roche, and Amgen are also advancing with innovative candidates, fueling competition in this dynamic and lucrative field.

Sign up for your early morning brew of the BizNews Insider to keep you up to speed with the content that matters. The newsletter will land in your inbox at 5:30am weekdays. Register here.

Join us for BizNews' first investment-focused conference on Thursday, 12 September, in Hermanus, featuring top experts like Frans Cronje, Piet Viljoen, and more. Get insights on electricity and exploiting SA's gas bounty from new and familiar faces. Register here.

SOURCE: REUTERS

Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s.

___STEADY_PAYWALL___